MarketBeat aggregates analyst ratings and Benzinga reports on ARS Pharmaceuticals, which saw Leerink Partners cut its price target to $24.00.

The entities involved

• MarketBeat →

  American personal finance blog

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • MarketBeat aggregates data on IDT Corporation stock performance.Mon 17:15
• Leerink partners →

  U.S. investment bank

  • Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
  • A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38
• Benzinga →

  American news channel

  • Benzinga reported on the recent stock price activity of SpaceX.Mon 02:14
  • Benzinga reported analyst expectations for Jabil.Mon 02:08

Related events

• Leerink raised its price target for UnitedHealth Group stock.Jun 19
• Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Jun 7
• Ascendiant Capital Markets increased the target price for Duos Technologies Group from $22.00 to $24.00, with an average rating of Moderate Buy.Sep 14
• MarketBeat aggregates sentiment on Liberty Broadband Corp (LBRDK) stock, which has received a target price downgrade from Citigroup.Aug 31
• Citigroup cut its price target for OLLI stock, and MarketBeat reported on OLLI.Aug 29